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MONOFLUOROACETIC ACID (COMPOUND 1080), ITS PHARMACOLOGY AND
TOXICOLOGY
ERNEST KUN, Department of Pharmacology, The University of California, San Francisco, San Francisco,
California 94143
ABSTRACT: The molecular mechanism of toxic action of fluoroacetate is analyzed in the perspective of
scientific developments of the past 30 years. Stereospecific enzymatic conversion of fluoroacetate via
fluoroacetyl –CoA + Oxalacetate to (-)-erythrofluorocitrate in mitochondria is the metabolic pathway
that converts the nontoxic fluoroacetate to the toxic intracellular effector molecule. The mode of
toxic effect of (-)-erythrofluorocitrate cannot be equated with its reversible inhibitory effect on a
mitochondrial enzyme (aconitase) as had been originally thought by Peters (1963) and is still
propagated in textbooks. Instead, the chemical modifications of inner mitochondrial membrane proteins
by (-)-erythrofluorocitrate, comprising a novel, as yet incompletely understood biochemical mechanism,
is the molecular basis of toxicity. Research is this new area eventually explain selective (speciesdependent) toxicity, the development of resistance to this poison and can lead to the scientific basis
of the development of antidotes.
INTRODUCTION
The discovery of detailed mechanism of action of highly toxic agents inevitably reveals new areas
of cellular physiology, as first pointed out by Claude Bernard (1). It is evident that if an agent in
minute quantities is capable of terminating life processes, the site action of the toxic substance
has to represent a vitally important biological system. Despite the plausibility of this axiom, only
relatively few poisons have been studied in sufficient depth to allow the precise identification of
their critical target systems, and their proposed mechanism of action are frequently borrowed from
concepts of a branch of biochemistry that happens to be fashionable at that time. As in all areas of
science, especially in biology, the scientific explanations of cellular physiology or, more correctly
stated, the scientific hypothesis that should predict (2) the operation of complex cellular processes,
reflect the developmental history of science. This is especially true of pharmacology that critically
depends for mechanistic interpretations on the developmental stage of both biochemistry and molecular
biology. At the time Sir Rudolph Peters (1963) in the early 1950s recognized that fluoroacetate
requires metabolic conversion to the fluorotricarboxylic acid, fluorocitrate (cf. 3) biochemistry was
preoccupied with “metabolic pathways”. This area should be defined as enzymatic interconversion of
small molecules. Explanation of cellular physiology by the great complexity of metabolic pathways was
the promise of “metabolic biochemistry”, which despite important advances in enzymology and intermediary
metabolism could not live up to expectations. It is now clear that without considering the metabolism
of macromolecules and of heterogenous, natably membrane systems, no understanding of cellular physiology
is possible, and metabolic pathways merely represent a first approximation similar to a wiring diagram,
which by itself can be misleading. In the following section I wish to examine the scientific evidence
that leads to the still popular metabolic explanation of fluoroacetate poisoning and then proceed to
new developments.
METABOLIC ACTIVATION
The metabolic hypothesis of fluoroacetate poisoning.
The main event that survived the test of time is the metabolic activation of fluoroacetate as
proposed by Peters (cf. 3). However, details of this process were unknown and required further chemical
and enzymological studies. The conversion of fluoroacetate (1080) to fluoroacetyl–CoA is presumed to
take place in much the same way as acetate is converted to AcCoA, except the rate of the fluoro analog
formation is probably much slower than acetate conversion to AcCoA, similar to results observed in all
enzymatic reactions of monofluoro-carboxylic acids(4, 5). The exact rate of F-acetyl-CoA formation is
still unknown. The next step, the enzymatic condensation of F-acetyl-CoA with oxalacetate has been
extensively studied in our laboratory (6, 7) and results are shown in Table 1.
Table 1. Summary of kinetic properties of citrate synthase from pig heart (cf. 4).

It is evident that the affinities of F- AcCoA and AcCoA toward the condensing enzyme are the same, but
the Vmax of the condensation reaction is only 1/350th with F-AcCoA as compared to AcCoA. This means
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that fluorocitrate formation proceeds at 1/350th the rate of citrate synthesis under comparable conditions
and effectively F-acetyl-CoA is a potent competitive inhibitor of citrate synthesis in an enzymatic
system. It can be predicted that large doses of acetate would be moderately effective in counteracting
the formation of the toxic fluorocitrate, by competing for F-AcCoA formation and therefore acetate may
diminish F-acetate toxicity. This was shown to be the case using glycerol-monoacetate that was somewhat
protective in monkeys against F-acetate poisoning (8). However, only large doses are effective as
would be anticipated from Table 1 and this agent only slows down fluorocitrate formation but does not
alter fluorocitrate toxicity.
The consecutive and most important product is formed from F-acetyl-CoA and oxalacetate and this
substance was identified in our laboratory by enzymatic (6, 7) and chemical (9) synthesis and its
precise sterochemistry established by NMR (6, 7) and X-ray diffraction (10, 11) to be (-)-erythrofluorocitric acid or expressed in more precise stereochemical nomenclature as 1R-2R-1-fluoro-2-hydroxy1, 2, 3-propanetricarboxylic acid. (Fig. 1) or 2R, 3R (-)-erythrofluorocitric acid, as shown in Fig. 1.

Fig. 1. This is the isomer described by Dummel and Kun (1969, J. Biol. Chem. 244,
2966) and defined as (-)-erythro-fluorocitrate by them. We report here structural
studies of the mirror image (enantiomer) of this isomer. Crystals of the complex
of the diethyl ester of (+)-erythro-fluorocitrate with (-)-methylbenzylamine were
studied by X-ray diffraction techniques. Since the absolute configuration of (-)methyl benzylamine has already been determined experimentally, the absolute
configuration of the (+)-erythro isomer of fluorocitrate is thereby established.
This isomer is shown to be noninhibitory with the enzyme aconitase, while its
racemate is a powerful inhibitor. Thus it is proved that the absolute configuration of the isomer of fluorocitrate that is formed from fluoroacetyl-CoA by the
enzyme citrate synthase, and that inhibits aconitase, is the 2R, 3R, isomer (cf. 11).
The metabolic conversion of F-acetate to the toxic factor (-)-erythrofluorocitrate is clearly a
slow process that can be modified by the preexistence of competing physiological metabolites and this
explains the slow onset of toxic symptoms after ingestion of F-acetate. The nature of the molecular
toxicology of (-)-erythrofluorocitrate has been proposed by the metabolic hypothesis to be an
inhibitory effect on the mitochondrial enzyme aconitase that maintains an equilibrium between citrate
and isocitrate. My concern about the correctness of this hypothesis is based on results of enzyme
kinetics.
Enzyme kinetics shows that with highly purified aconitase enzymes the inhibition is competitive
and reversible (Fig. 2).
Fig. 2. Competitive inhibition of cytoplasmic (A) and mitochondrial
(B) aconitase of pig liver by (-)-erythrofluorocitrate. Rates of
cis-aconitate formation from citrate were measured at 240 nm (10)
in 0.15 M Tris-HCl, pH 7.5, at 25°. In A, 1.5µg (protein) of
cytoplasmic aconitase, and in B, 32 ug of mitochondrial aconitase,
were used per test system (5-cm light path; 3-ml volume) at varied
concentrations of citrate (abscissa). Curve 1, 500 µM fluorocitrate; 2, 100 µM fluorocitrate; 3, no fluorocitrate (cf. 12).
This information predicts that if citrate accumulates, as is the case in F-acetate poisoning, the
inhibition by fluorocitrate should disappear; therefore, the metabolic hypothesis of F-acetate poisoning,
based on reversible kinetics, cannot be correct because despite large citrate accumulation in cells, Facetate poisoning is not alleviated.
The metabolic theory has been tested in our laboratory with a number of other F-substituted
carboxylic acid analogs of the citric acid cycle (cf. 5) which proved to be selective reversible
competitive inhibitors of mitochondrial as well as cytoplasmic enzymes. The inhibitory effect of some
F-carboxylic acids (e.g. monofluoro-oxalacetate on malate dehydrogenase) is much larger than the inhibitory effect of (-)-erythrofluorocitric acid on aconitase, yet F-carboxylic acids that cannot be effectively converted to (-)-erythrofluorocitric acid are relatively nontoxic. Properties of F-carboxylic acids
are summarized in Table 2.
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Table 2. Substrate and inhibitory properties of F-carboxylic acids (cf. 5).

No.

Enzyme

F-carboxylic acid

Km

Kj

LEGEND: MDH = malate dehydrogenase; GOT = glutamate oxalacetate aminotransferase; GDH = glutamate
dehydrogenase; LDH = lactate dehydrogenase; Ma = molecular activity; (S) = with physiological substrate;
(F-S) = with fluoro-analogue.
If the enzyme inhibitory mechanism of F-acetate poisoning based on reversible competitive
inhibition were correct, then any of the F-carboxylic acid analogs of the citric acid cycle that
competitively inhibited a citric acid cycle enzyme should be a highly potent poison, which was not
the case.
These results therefore oppose the metabolic hypothesis of F-acetate toxicity that is based on a
reversible competitive enzyme kinetics.
The metabolic inhibitory hypothesis of F-citrate toxicity is also incompatible with results shown
in Table 3. Depending on the cellular origin of mitochondria, addition of F-citrate not only does not
inhibit mitochondrial O2 uptake, but with glutamate and liver mitochondria, respiration is augmented by
fluorocitrate (13). Concentrations of F-citrate employed were sufficient to inhibit aconitase, yet
a significant increase in O2 uptake and obviously ATP synthesis was maintained by glutamate despite
aconitase inhibition. It follows that in vivo availability of ubiquitous glutamate as mitochondrial
substrate results in a bypass of the inhibition of aconitase-dependent mitochondrial energy production,
as tested by conventional metabolic assays (Table 3).
Table 3. The effect of synthetic Monofluorocitrate
(0.6 mM) on respiration and citrate accumulation of
mitochondria prepared from various tissuesa (cf. 13).

a
All rates are expressed as µmoles/g protein/30 min; all contents as moles/g protein. O2’, polarographic O2 uptake calculated from
initial rates; O2", Warburg respirometer O2 uptake measured over 30-minutes duration; C, citrate formed in. Warburg vessels. Substrates
were present at a final concentration of 5 mM, and ADP at 2.3 mM. Fluorocitrate (0.6 mM) was added where indicated.
b
No increase over endogenous.
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The main lesson deduced from these data is that reversible competitive inhibition of aconitase or
any other citric acid cycle enzyme by a F-carboxylic acid does not inhibit cellular respiration and
energy production as, for example, is the case if one inhibits mitochondrial cytochrome oxidase by
cyanide.
Reactions of (-)-erythrofluorocitric acid with mitochondrial proteins.
We have known ever since 1963 (7) that (-)-erythrofluorocitric acid exerts an inhibitory effect on
aconitase activity of crude mitochondrial extracts that is not explained by a linearly competitive
reversible inhibition, as illustrated in Fig. 2. Much smaller concentrations of (-)-erythrofluorocitric
acid than would be predictable from K-j values derived from initial velocity analysis cause a complete
inactivation of this enzyme, if sufficient time is allowed for this process of inactivation to proceed
as illustrated in Fig. 3. The effect under these conditions is irreversible and is reminiscent of
kinetics of enzyme inactivation by active site-oriented irreversible inhibitors.

Fig. 3. Lower curve: rate in the presence of 1
µM F-ci (cf. 4).
One possibility appeared to be an enzymatic conversion of (-)-erythrofluorocitrate to a reactive species,
such as F-aconitate, that could alkylate thiol groups of the enzyme. However, it was shown (14) that
purified aconitase catalyzes the defluorination of (-)-erythrofluorocitric acid in the presence of cysteine
and Fe 2+ and converts it to hydroxy-citrate, which is only a reversible inhibitor of aconitase and does
not bind to aconitase protein. Subsequent work in our laboratory with [14c] labeled (-)-erythrofluorocitrate of high specific activity opened up a new territory of investigation (16). It was shown that in
crude extracts of mitochondria (-)-erythrofluorocitrie acid was bound to macromolecules (Fig. 4).

Fig. 4. Inner mitochondrial membrane vesicles were incubated
with 14c-(-)-erythrofluorocitrate and after dissolution in
guanidine HCl passed through a Sephadex G-200 molecular filter
column. Unreacted F-citrate separates (peak at right) from
protein bound F-citrate (cf. 15).
Furthermore, evidence was obtained that at least three molecular species of proteins served as ligands
for (-)-erythrofluorocitrate, as illustrated in Fig. 5.
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Fig. 5. G-200 Sephadex chromatography, I, II and
inflection on II indicate 3 molecular species of
F-ci binding proteins (cf. 15).

The chemical bond between (-)-erythrofluorocitric acid and protein resisted acid treatment but was
hydroxylamine sensitive, yielding a fluorocitrate derivative tentatively identified as a hydroxamate of
(-)-erythrofluorocitric acid (Fig. 6).

Fig. 6. Separation of (-)-erythrofluorocitrate
from its hydroxamate derivative by paper
electrophoresis (cf. 15).

Synthesis of authentic 2-hydroxamate of (-)-erythrofluorocitric acid was only recently successful (16)
and the identification of the chemical bond between (-)-erythrofluorocitrie acid and proteins is
presently pursued.
The process of protein fluorocitrylation is illustrated in Fig. 7.
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200
Fig. 7. Process of protein fluorocitrylation.
Abscissa = µM F-citrate, Ordinate = rate of
protein binding (cf. 15).
The reaction is clearly a catalytic process, but we are still uncertain about the nature of its
detailed mechanism that is, I believe, the central problem of fluorocitrate toxicity. One experimentally
well-documented consequence of macromolecular association of (-)-erythrofluorocitric acid with mitochondrial proteins is the irreversible inactivation of metabolism-connected citrate in and outflux in
isolated mitochondria (15). There is controversy about the relevance of another type of citrate flux
in mitochondria, which is termed as exchange diffusion and is measured in the absence of metabolism,
with inhibitors of metabolic functions present. I believe that the metabolism-connected much slower
rate of citrate transport that we are studying is the one that is inactivated by nmolar concentrations
of (-)-erythrofluorocitric acid and this process is the physiologically significant transport of citrate.
It can be postulated that in certain animal species, where the biosynthesis of the brain transmitter
substance acetylcholine is entirely dependent on the export of intramitochondrially generated citric
acid, the membrane transport site of mitochondria for citrate may be a target site that could explain
the neurotoxic effect of (-)-erythrofluorocitric acid. I believe this to be an interesting but, perhaps
not crucial, mechanism and our research work tends to indicate an even more complex inner mitochondrial
system that, according to my present state of information, is the real target site of F-acetate poisoning
on a molecular level. Briefly, we isolated a new mitochondrial protein, which is likely to be the 180 kd
protein shown in Fig. 5. Characteristics of this protein are shown in Fig. 8, which is a gel electrophoresis pattern at various stages of purity.

Fig. 8. Gel electrophoresis (SDS) characteristics
of the new mitochondrial protein at various stages
of purity. 1 = Purified aconitase, 2 = Fe-S
protein after isoelectric purification, 3 = Fe-S
protein after aminohexyl sepharose chromatography.
Main protein = 40 kd., 4 = Standards: BSA and
cytochrome C.
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In the gel the subunit structure is illustrated, corresponding to a major 40 kd subunit of the tetrameric
protein (160 kd), plus apparently associated further subunits that make up the sum of 180 kd mass. This
protein is an iron sulfur protein which contains also covalently bound glutathione. Its physiological
function is unknown except that it binds (-)-erythrofluorocitrate; and, according to present hypothesis,
transfluorocitrylation to other iron sulfur proteins, like aconitase, takes place in successive enzymatic
steps. Since specific iron-sulfur proteins in the mitochondrial electron transport system exist at
critical stages of energy transfer (sites of oxidative phosphorylation), the possibility exists that the
ultimate toxic mechanism of (-)-erythrofluorocitrate, and, of course, fluoroacetate, is related to a
chemical blocking of mitochondrial energy transduction. This is our present state of ignorance related
to this complex problem. It is anticipated that clarification of these questions will reveal a hitherto
unsuspected macromolecular membrane apparatus, but very much needed research in these basic areas can
only promise slow progress.
Probable correlations of biochemical mechanisms to animal toxicology.
The macroscopic toxicology of fluoroacetate is not very revealing, except for the well-documented
latency which can vary -- as predictable from the known pathway of intramitochondrial (-)-erythrofluorocitric acid biosynthesis. In susceptible species the effect appears to be neurotoxicity, with
repeated onset of convulsions and eventual central paralysis. As in all types of convulsive seizures,
loss of consciousness is a general accompaniment, thus contrary to laymen's impressions, death by
fluoroacetate poisoning is not unusually troublesome. It is not known what the precise reasons for
neurotoxicity are, except for the experimental fact (17) that submicrogram amounts of (-)-erythrofluorocitric acid if injected into the third cerebral ventricle causes relatively rapid neurotoxic death. If
this effect is due to inhibition of cholinergic centers in the brain, then the citrate export-dependent
acetyl choline biosynthesis-related mechanism (15) may play an important role. However, very little is
known about the function of cholinergic centers in the central nervous system. It has to be also
assumed that in species that respond with neurotoxicity to fluoroacetate extramitochondrial, sources of
AcCoA must be negligible in the target cells. In some species death is presumably due to cardiac arrest,
but it is unclear whether or not this effect is due to central or peripheral mechanisms.
Questions have been asked whether or not secondary intoxication, i.e. toxicity by ingestion of Facetate poisoned animals, is due to F-acetate or (-)-erythrofluorocitric acid. Based on calculated
metabolic rates of F-carboxylic acids, as discussed earlier, the most probable substance that may cause
secondary poisoning is remaining unmetabolized F-acetate itself.
An unsolved problem of F-acetate toxicology is the marked variation in susceptibility and development of tolerance depending on animal species, a matter that is not explainable by the "metabolic
hypothesis" of the toxicology of F-acetate. Significant contributions to this subject were made by
Australian colleagues (18-21) who showed that apparent genetic determinants can modify the development
of susceptibility or resistance to F-acetate in various species and that this phenomenon is unrelated
to metabolic defluorination of F-acetate (22). Again, this entire phenomenology is unexplained by the
blocking of an ubiquitous metabolic pathway (3), and I predict that a better understanding of the inner
mitochondrial membrane-related novel system is likely to yield clues.
In conclusion, I believe that the most rational application of F-acetate in agriculture and animal
ecology should be done on the basis of selective protection of desired species by the feeding of an
appropriate antidote to species that are to be preserved. This, of course, depends on much research on
a basic level, which has yielded possible approaches, but under present circumstances research in this
field appears to be not favorable because of apprent lack of appreciation of this problem by funding
agencies.
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